iNtRON Biotechnology Inc - Asset Resilience Ratio

Latest as of September 2025: 10.90%

iNtRON Biotechnology Inc (048530) has an Asset Resilience Ratio of 10.90% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 048530 liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets

₩8.58 Billion
≈ $5.81 Million USD Cash + Short-term Investments

Total Assets

₩78.70 Billion
≈ $53.34 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2012–2024)

This chart shows how iNtRON Biotechnology Inc's Asset Resilience Ratio has changed over time. See 048530 total equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down iNtRON Biotechnology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see iNtRON Biotechnology Inc market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩8.58 Billion 10.9%
Total Liquid Assets ₩8.58 Billion 10.90%

Asset Resilience Insights

  • Moderate Liquidity: iNtRON Biotechnology Inc has 10.90% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

iNtRON Biotechnology Inc Industry Peers by Asset Resilience Ratio

Compare iNtRON Biotechnology Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Fortress Biotech Inc
NASDAQ:FBIO
Biotechnology 11.59%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Biotechnology 0.58%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
BrightGene Bio Medical Technology C
SHG:688166
Biotechnology 1.00%
BioArctic AB (publ)
ST:BIOA-B
Biotechnology 72.35%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%

Annual Asset Resilience Ratio for iNtRON Biotechnology Inc (2012–2024)

The table below shows the annual Asset Resilience Ratio data for iNtRON Biotechnology Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 17.85% ₩15.42 Billion
≈ $10.45 Million
₩86.37 Billion
≈ $58.53 Million
-40.14pp
2023-12-31 57.99% ₩57.18 Billion
≈ $38.75 Million
₩98.61 Billion
≈ $66.83 Million
+24.40pp
2022-12-31 33.59% ₩47.35 Billion
≈ $32.09 Million
₩140.96 Billion
≈ $95.53 Million
-20.85pp
2021-12-31 54.44% ₩83.49 Billion
≈ $56.58 Million
₩153.37 Billion
≈ $103.93 Million
-11.37pp
2020-12-31 65.81% ₩66.16 Billion
≈ $44.84 Million
₩100.54 Billion
≈ $68.13 Million
+2.50pp
2019-12-31 63.32% ₩56.37 Billion
≈ $38.20 Million
₩89.03 Billion
≈ $60.34 Million
+24.70pp
2018-12-31 38.62% ₩21.16 Billion
≈ $14.34 Million
₩54.80 Billion
≈ $37.13 Million
-3.16pp
2017-12-31 41.77% ₩19.06 Billion
≈ $12.92 Million
₩45.63 Billion
≈ $30.92 Million
+2.51pp
2016-12-31 39.26% ₩23.40 Billion
≈ $15.86 Million
₩59.61 Billion
≈ $40.39 Million
+29.03pp
2015-12-31 10.23% ₩4.13 Billion
≈ $2.80 Million
₩40.37 Billion
≈ $27.36 Million
-3.92pp
2012-12-31 14.15% ₩2.78 Billion
≈ $1.88 Million
₩19.64 Billion
≈ $13.31 Million
--
pp = percentage points

About iNtRON Biotechnology Inc

KQ:048530 Korea Biotechnology
Market Cap
$77.34 Million
₩114.13 Billion KRW
Market Cap Rank
#20176 Global
#1162 in Korea
Share Price
₩3610.00
Change (1 day)
-3.48%
52-Week Range
₩2915.00 - ₩6650.00
All Time High
₩46250.00
About

iNtRON Biotechnology, Inc. engages in the development of novel drugs in South Korea. It develops bacteriophage and endolysin based drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.